De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SanBio Beheer

Beheer criteriumcontroles 2/4

De CEO SanBio's is Keita Mori, benoemd in Feb2013, heeft een ambtstermijn van 11.67 jaar. bezit rechtstreeks 8.74% van de aandelen van het bedrijf, ter waarde ¥ 7.89B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 11.6 jaar.

Belangrijke informatie

Keita Mori

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.7yrs
Eigendom CEO	8.7%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	11.6yrs

Recente managementupdates

Recent updates

CEO

Keita Mori (57 yo)

11.7yrs

Tenure

Mr. Keita Mori, MBA, is a Co-Founder of SanBio, Inc., and served as its Chief Executive Officer and served its Co- Chief Executive Officer since 2001 until October 1, 2018. Mr. Mori has been the President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kawanishi	Co-Founder & Executive Chairman	11.7yrs	geen gegevens	17.81% ¥ 14.5b
Keita Mori	Co-Founder	11.7yrs	geen gegevens	8.74% ¥ 7.1b
Yoshihiro Kakutani	Corporate Officer of Management Administration	no data	geen gegevens	geen gegevens
Greg Gillas	Senior Vice President of Human Resources & Corporate Services	no data	geen gegevens	geen gegevens
Naoki Tsukahara	Senior Corporate Officer	2.9yrs	geen gegevens	geen gegevens
Kazumi Sawaguchi	Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan	2.8yrs	geen gegevens	geen gegevens
Keizo Nakada	Corporate Officer & Head of Production	2.3yrs	geen gegevens	geen gegevens
Shinya Hirata	Corporate Officer & Head of Research and Development	2.2yrs	geen gegevens	geen gegevens
Dai Chida	Senior Scientific Advisor	no data	geen gegevens	geen gegevens
Masumi Akahori	In charge of IR	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 4592 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kawanishi	Co-Founder & Executive Chairman	11.7yrs	geen gegevens	17.81% ¥ 14.5b
Keita Mori	Co-Founder	11.7yrs	geen gegevens	8.74% ¥ 7.1b
Noboru Kotani	Independent External Director	11.6yrs	geen gegevens	0.23% ¥ 186.4m
Yoichi Sato	External Auditor	5.3yrs	geen gegevens	geen gegevens
Toshimichi Ueda	External Auditor	11.6yrs	geen gegevens	0.0092% ¥ 7.5m
Masaaki Tanahashi	External Auditor	6.5yrs	geen gegevens	geen gegevens

11.6yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4592 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.6 jaar).

SanBio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Co., Ltd. Announces Board Changes

Less than half of directors are independent

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Recent updates

New major risk - Revenue and earnings growth

Sanbio Co., Ltd. Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation

SanBio Company Limited to Report Q2, 2025 Results on Sep 17, 2024

Price target increased by 20% to JP¥960

Price target increased by 23% to JP¥983

New major risk - Revenue and earnings growth

SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

SanBio Company Limited to Report Q1, 2025 Results on Jun 13, 2024

New major risk - Revenue and earnings growth

Price target decreased by 30% to JP¥1,214

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

Price target increased by 18% to JP¥2,100

Forecast to breakeven in 2027

SanBio Company Limited to Report Fiscal Year 2024 Results on Mar 18, 2024

Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

New major risk - Financial position

SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

SanBio Company Limited to Report Q3, 2024 Results on Dec 14, 2023

SanBio Company Limited to Report Q2, 2024 Results on Sep 15, 2023

Consensus revenue estimates fall by 15%

SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan

Price target increased by 13% to JP¥2,290

No longer forecast to breakeven

SanBio Company Limited to Report Q1, 2024 Results on Jun 14, 2023

Price target increased by 12% to JP¥2,465

No longer forecast to breakeven

Price target increased by 12% to JP¥2,465

SanBio Company Limited to Report Fiscal Year 2023 Results on Mar 16, 2023

Forecast to breakeven in 2026

SanBio Co., Ltd. Announces Board Changes

SanBio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Less than half of directors are independent

SanBio Company Limited to Report Q3, 2023 Results on Dec 15, 2022

Sanbio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Price target decreased to JP¥2,233

SanBio Company Announces Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

Price target decreased to JP¥2,200

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2023

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Less than half of directors are independent

Sanbio Group Provides an Update on One-Year Analysis of the Phase 2 STEMTRA Trial

Sanbio Company Limited Announces Filing with Japan’S Ministry of Health, Labour, and Welfare for Manufacture and Marketing Approval as A Regenerative Medicine Product for the Investigational Product Sb623

Price target increased to JP¥2,900

SanBio Company Limited announced that it expects to receive ¥33.75 million in funding from Nomura Securities Co., Ltd.

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

Corporate Officer & Business Head of Japan/Asia Hiroshi Yamamoto has left the company

Price target increased to JP¥2,660

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

Sanbio Company Limited Presents STEMTRA Phase 2 Trial Results At the 44Th Annual Meeting of the Japan Society of Neurotraumatology

SanBio Company Limited to Report Fiscal Year 2021 Results on Mar 17, 2021

SanBio Company Limited Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Price target lowered to JP¥2,683

New 90-day low: JP¥1,388

Price target lowered to JP¥2,683

SanBio Company Limited to Report Q3, 2021 Results on Dec 15, 2020

Tokio Marine & Nichido Fire Insurance Co., Ltd. agreed to acquire 9.74% stake in CareNet, Inc. (TSE:2150) from SanBio Company Limited (TSE:4592).

SanBio Company Limited Appoints Hiroyasu Narita as Head of Clinical Development, Effective from October 1, 2020

SanBio Company Limited to Report Q2, 2021 Results on Sep 14, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd